COMPARISON OF FOSFOMYCIN TROMETAMOL WITH CIPROFLOXACIN FOR UNCOMPLICATED UTI DUE TO E.COLI IN WOMEN

heri budiono, Sunaryo Hardjowijoto, Tarmono Djojodimedjo, Doddy M Soebadi, Agung Dwi Wahyu Widodo, Budiono Budiono

Abstract


Objective: To compare clinical therapeutic effects (frequency, dysuria, and pyuria), microbiology, pharmacokinetics index Cmax/MIC Fosfomycin Trometamol 3 gr single dose with Ciprofloxacin 2 x 500 mg/12 hours for 5 days in the treatment of uncomplicated UTI in women due to Escherichia coli (E.Coli). Materials & Methods: Experimental observational design from February until July 2013. Twenty two women with uncomplicated UTI due to E.Coli performed clinical and microbiological examination. Pharmacokinetics index (Cmax/MIC) is looked for. Patients are divided 2 group, Ciprofloxacin 500 mg/12 hours 5 days and Fosfomycin Trometamol single dose. Repeat clinical and microbiological evaluation is performed in 7 days after therapy. Statistic analysis use Chi Square test, Paired T test, and Independent T test. Results: In the treatment of uncomplicated UTI in women, Fosfomycin Trometamol single dose therapy provides clinical cure (dysuria 81.2%, p = 0.338, frequency 90.9%, p = 0.004, pyuria 90.9%, p = 0.009) much better than Ciprofloxacin 500 mg/12 hours 5 days. Fosfomycin Trometamol single dose therapy also provides bacteriological eradication (100%) better than Ciprofloxacin 500 mg/12 hours 5 days (p = 0.035). Fosfomycin Trometamol single dose had a higher pharmacokinetics index (Cmax/MIC) compared to Ciprofloxacin 500 mg/12 hours (p = 0.035). Conclusion: Fosfomycin Trometamol single dose therapy is superior to Ciprofloxacin 500 mg/12 hours 5 days in the treatment of uncomplicated UTI in women. Keywords: Therapeutic effect, fosfomycin trometamol, ciprofloxacin, uncomplicated UTI, Escherichia coli.

Full Text:

PDF

References


Stamm WE, Hooton TM. Current concepts, management of urinary tract infections in adults. The New England Journal of Medicine; 1993. p. 1328-35.

Reynard J, Brewster S, Biers S. Infections and inflamatory conditions. In: Albala DM, Morey AF, Gomella LG (ed); Oxford Handbook of Urology. 1st Ed. Oxford University Press; 2006. p. 133-84.

Schaeffer A, Schaeffer E. Infections of the urinary tract. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (ed); Campbell-Walsh Urology. 10th ed. Philadelphia: Elsevier-Sounders; 2012. p. 257-326.

Nguyen HT. Bacterial infections of the genitourinary tract. In: Tanagho EA, Mc Aninch (ed); Smiths General Urology. 17th ed. McGraw Hill; 2008. p. 193-218.

Schaeffer A. Urinary tract infections. In: Gillenwater JY, Grayhack JT (ed); Adult and Pediatric Urology. 4th ed. Philadelphia: Lippincott Williams Wilkins; 2002. Chapter 4.

Hooton TM. The epidemiology of urinary tract infection and the concept of significant bacteriuria. Infection 18 Medizin Verlag GmbH Munchen; 1990. Suppl 2.

Data of Urology Department Dr. Soetomo Hospital; 2012.

Bacterial Map of Dr. Soetomo Hospital Surabaya January–Juny 2009 period. Clinical Microbiology Department Dr. Soetomo Hospital Surabaya; 2009.

Sastroasmoro S, Suseno U, Pakaya R. Penggunaan ciprofloxacin di Indonesia. Health Technology Assessment, Departemen Kesehatan RI; 2005.

Grabe M, Bjerklund-Johansen TE, Botto H, Naber KG, Wagenlehner F. Guidelines on urological infections. In EAU Guidelines edition presented at the 25th EAU Annual Congress, Barcelona; 2010.

G.C. Schito, Why fosfomycin trometamol as first line therapy for uncomplicated UTI? International Journal of Antimicrobial Agents; 2003. p. S79-83.

Setiabudy R. Antimikroba Lain. In: Ganiswara SG (ed). Farmakologi dan Terapi. 4th ed. Balai Penerbit FKUI Jakarta; 1995. p. 682-5.

Fosfomycin Thromethamine product monograph. PT. Zambon Indonesia; 2012.

www.drugs.com/monograph/fosfomycin-tromethamine.html

Katzung BG, Masters S, Trevor A. Basic and clinical pharmacology. 8th ed. Lange; 2001,

Mathew E Levinson. Pharmacodynamic of antimicrobial drugs. Infectious Disease Clinics of North America; 2004. p. 451-65.

Ceran N, Mert D, Kockdogan FY. A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections. J Infect Chemoter; 2010. p. 424-30.

Bozkurt OF, Kara C, Akarsu S. Comparison efficacy of single dose fosfomycin with ciprofloxacin in the treatment of urinary tract infection in symptomatic women. Turk Uroloji Dergisi. 2008; 34: 360-2.

Kunin CM. Urinary tract infections in females. Clinical infectious disease. Department of Internal Medicine, Ohio State University; 1994.

Iswar IS. The Susceptibility pattern of urine bacteria from the Surgery Departement at Sanglah Hospital. Free Papers; 2004. Simposium Evidence Based Use of Antimicrobials in the Era of Alaming Resistance, Jakarta 2-3 July 2005.

Juniastuti, Kuntaman, Mudihardi E. Bacterial isolates causing UTI and the resistance patterns in Department of Clinical Microbiology, Dr. Soetomo General Hospital, Surabaya. Free Papers; 2005. Simposium Evidence Based Use of Antimicrobials in the Era of Alaming Resistance, Jakarta 2-3 Juli 2005.

Oteo J, Bautista V, Lara N. Pararel increase in community use of fosfomycin and resistance to fosfomycin in extended spectrum B-lactamase (ESBL) producing Escherichia Coli. Journal Antimicrobial Chemotherapy. 65th ed. 2010. p. 2459-63.

Barger A, Fuhst A, Wiedemann B. Pharmacological indices in antibiotic therapy. Journal of Antimicrobial Chemotherapy. 2003; 52: 893-8.

Mathew E Levinson. Pharmacodynamic of antimicrobial drugs. Infectious Disease Clinics of North America; 2004. p. 451-65.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.